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OBJECTIVES: To describe health resource utilization (HRU) patterns among 
patients with systemic lupus erythematosus (SLE) prescribed belimumab in U.S 
clinical practice settings. METHODS: OBSErve (BLM117295) is a multi-center 
retrospective medical chart review study. Ninety-two rheumatologists from non-
academic-centers in the U.S randomly identified adult SLE patients in their 
practice who had received at least 8 infusions of belimumab (10mg/kg) as part of 
usual-care. Index-date is the date of the first belimumab infusion. Physicians 
assessed the following data corresponding to the 6 months pre- and post-index 
periods: patient demographics, comorbidities, SLE disease characteristics/ 
outcomes, and HRU (hospitalization/ER/office-visits, ancillary care 
(physical/occupational therapy/home health), medications). Patterns of HRU in 
the 6 months pre- and post-index period are reported from univariate 
(comparative) analysis and two-sided tests of significance (p<0.05). RESULTS: 
Physicians abstracted 501 eligible patient-charts (mean age:41.3yrs, female:89%, 
Caucasian:53%, black/African-American:24%, Hispanic:18%, other:5%; 
Medicare:13%, Medicaid:14%, commercial-insurance:62%; diagnosed with SLE <5 
yrs ago:56%); 3%/77%/20% had mild/moderate/severe disease at baseline, per 
physician judgment. In the pre-index period, concomitant medications included 
oral steroids(78%), antimalarials(70%), immunosuppressants(61%) and 
NSAIDs(16%). In post-index period, among those on oral steroids, 9% 
discontinued steroids and 77% decreased the dose. Percentage of patients with 
>1 hospitalization (pre-index:5%;post-index:2%;p=0.03), >1 ER visits (pre-
index:15%;post-index:6%;p=0.001), >1 unscheduled treating physician visits (pre-
index:52%;post-index:30%;p<0.001), and those receiving any ancillary care (pre-
index:15%;post-index:6%;p=0.001) decreased from pre-index to post-index 
period. The mean number of hospitalizations (pre-index:0.6;post-
index:0.2;p=0.02), ER visits (pre-index:0.2;post-index:0.07;p<0.001), unscheduled 
visits to treating physician (pre-index:1.0;post-index:0.5;p<0.001) and visits to 
other specialty physicians (pre-index:2.0;post-index:1.4;p=0.001) also decreased 
from pre-index to post-index period. CONCLUSIONS: Resource utilization 
decreased in a sample of belimumab treated patients in the first 6-months, in 
comparison to the pre-index period. Association of these observed HRU patterns 
with clinical outcomes and the implications of these observed HRU patterns for 
payers warrants further study.  
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OBJECTIVES: To estimate the economic burden associated with SLE, stratified by 
flare severity in a commercially-insured population in the United States. 
METHODS: In this retrospective, observational study, commercially insured 
adults aged 18-64 years with at least one SLE-related inpatient or emergency 
room (ER) claim or at least two SLE-related outpatient visits at least 30 days apart 
with a rheumatologist between July 1/2004 and December 31, 2008, were 
identified in the MarketScan Commercial Claims and Encounters database. Non-
SLE controls were matched (1:1) to SLE cases on age group, gender, region, and 
index year using propensity scores. Mild, moderate, and severe flares were 
identified in the follow-up period using a claims-based algorithm. A log 
transformed linear regression model was applied to estimate the incremental 
annual economic burden associated with SLE flares by severity. RESULTS: A total 
of 13,460 SLE cases were matched to non-SLE controls. During the variable length 
follow-up period of at least 12 months in duration, SLE cases had a higher rate of 
hospitalization (49.7% vs. 27.7%; p<0.001) and ER visits (66.7% vs. 43.7%, p<0.001) 
compared to non-SLE controls. Among SLE cases with no flares (11.9%), 
mild/moderate (65.9%) and severe flares (22.2%), annualized all-cause direct 
medical costs were $14,945, $21,606 and $64,578 respectively. Multivariate-
adjusted incremental annualized direct medical costs for SLE cases with no 
flares, mild/moderate, and severe flares were $441, $3,606 (p<0.05) and $18,953 
(p<0.05), respectively. CONCLUSIONS: The direct medical costs of patients with 
SLE were significantly higher than controls, with costs increasing substantially 
as the severity of flares increase. Further research examining outcomes 
associated with interventions in patients with SLE may help identify potential 
improvements in patient care and outcomes (including reduction in severe SLE 
flares), while reducing the economic burden of SLE to employers and payers.  
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OBJECTIVES: Treating the approximately 100,000 patients in the United States 
today with sickle cell disease (SCD) can be costly. Identifying the main cost 
drivers of SCD is essential to developing appropriate interventions and 
improving patient outcomes. Real-world insights into the main cost drivers of 
SCD were gathered from the perspective of payers and physicians actively 
treating patients. METHODS: A systematic literature review was conducted on 
resource use and cost drivers associated with SCD, guiding our questionnaire 
development. Three physicians from academic and private practice and nine 
payers (medical, pharmacy or case management directors of large regional or 
national plans with commercial, Medicaid and/or managed Medicaid patients) 
were interviewed about their SCD patient management, resource utilization, and 
cost drivers experiences. RESULTS: Evidence from the published literature 
suggests that a small number of patients account for the majority of resource 
utilization and costs. Studies assessing resource utilization by SCD patients 
reported that 25% of patients accounted for 75% (Medicaid) and 83% (privately 
insured) of costs, and nearly 80% of total inpatient days. Physicians and payers 
indicated that about 10-30% of patients are responsible for the majority of costs. 
Payers also revealed that SCD patients can have “catastrophic” costs, and rank 
among the plan’s top 20 most costly patients. Payers and physicians all reported 
that SCD patients faced barriers to accessing primary care, leading to 
hospitalization and emergency department overuse. Barriers included low 
Medicaid reimbursement rates, lack of transportation, and low health care 
literacy. CONCLUSIONS: Results from this systematic literature review and 
interviews with physicians and payers identify barriers in access to care as a key 
driver for hospitalization and emergency department overuse by SCD patients. 
This suggests that effectively designed disease management programs can help 
patients avoid acute care utilization, delivering better patient care with lower 
costs.  
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OBJECTIVES: To describe the relationship between resource utilisation, inhibitor 
status, treatment regimen and bleed frequency in the HERO Study. METHODS:  
A post-hoc descriptive analysis of adult people with haemophilia (PWH)  
and children with haemophilia (CWH) aged <18 years, with (WI) and without 
inhibitors (WOI), from 8 countries with home treatment 
(AR/CN/DE/FR/IT/SP/UK/US) are presented. RESULTS: Most PWH (431 WOI, 84 WI) 
and CWH (411 WOI, 42 WI) were without inhibitors. Use of on-demand and 
prophylaxis treatment was evenly distributed among PWH (180 on-demand, 203 
prophylaxis); most CWH were on prophylaxis (87 on-demand, 335 prophylaxis). 
Mean/median bleeds per year were higher in PWH WOI on prophylaxis (14.9/5) 
than on-demand (10.3/2), but lower in WI on prophylaxis (5.6/2) than on-demand 
(15.6/7). Higher-risk activities were reported more for PWH on prophylaxis (15% 
vs. 8%) and with decreasing annual bleed rates (15%-9%). Mean/median annual 
bleeds were higher in CWH WOI on on-demand (7.5/3) than prophylaxis (5.2/3) 
and in WI on prophylaxis (12.1/8) than on-demand (9.2/6). Mean annual 
haemophilia treatment centre (HTC) visits were slightly higher on prophylaxis 
for PWH (prophylaxis 4.5, on-demand 3.7) and CWH (prophylaxis 5.6, on-demand 
4.8). For CWH, median HTC visits increased with increasing bleed frequency (2-
5/year). Nurse involvement in haemophilia management was more frequently 
reported by PWH on prophylaxis (57%) than on-demand (45%). Nurse (37%-57%), 
social worker (9%-32%), and physiotherapist (20%-37%) involvement increased 
with bleed frequency in PWH. CWH WI reported more nurse involvement on 
prophylaxis (71%) than on-demand (57%) but less social worker involvement (8% 
vs. 29%); physiotherapists were more frequently involved for CWH WOI on 
prophylaxis (34%, on-demand 23%). CONCLUSIONS: HTC utilisation was higher 
for PWH/CWH on prophylaxis; for CWH, bleed frequency increased utilisation. 
Involvement of physiotherapy and social work was less than expected for 
PWH/CWH, but could positively impact bleed rate; and, overall utilization 
deserves further study.  
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OBJECTIVES: To describe the associations between resource utilisation and 
negative experiences (NEs) with employment, relationships and intimacy in the 
HERO Study. METHODS: A post-hoc descriptive analysis of adult people with 
haemophilia (PWH) and parents of affected children from 8 countries 
(AR/CN/DE/FR/IT/SP/UK/US). RESULTS: Of 515 PWH, 77% reported NEs with work, 
32% relationships (52% intimacy) or 26% telling friends about their haemophilia. 
Of 453 parents, 61% reported NEs with work, 41% telling friends; 77% reported 
impact on unaffected siblings. PWH reporting work-related NEs were less often 
employed (59% vs 80%) and more frequently sought HTC advice on employment 
(32% vs 25%), but fewer with NEs described this advice as very helpful. Parents 
with/without NEs were equally employed. More PWH reporting relationship NEs 
reported NEs with intimacy (30% vs 12%) and friends (39% vs 27%). More PWH 
reporting NEs telling friends reported NEs with relationships (33% vs 22%) and 
intimacy (32% vs 18%). PWH reporting impacts on intimacy were more likely to 
have discussed intimacy with the HTC, but less likely to report the discussions as 
very helpful. More parents reporting NEs telling friends reported impacts on 
siblings (28% vs 18%). Haemophilia management including nurses and social 
workers was more often reported for PWH with any NE. More PWH reporting NEs 
with relationships or friends reported treatment for psychological conditions. 
Parents reporting work-related NEs reported more mean/median HTC visits per 
year (6.3/3 vs 4.1/2). Social worker involvement and treatment for psychological 
